Sensei Biotherapeutics, Inc.
SNSE
$21.45
$0.452.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.63M | 11.37M | 12.24M | 12.77M | 13.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.59M | 24.65M | 27.63M | 30.21M | 31.66M |
| Operating Income | -20.59M | -24.65M | -27.63M | -30.21M | -31.66M |
| Income Before Tax | -21.09M | -24.14M | -26.82M | -29.03M | -30.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.09 | -24.14 | -26.82 | -29.03 | -30.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.09M | -24.14M | -26.82M | -29.03M | -30.16M |
| EBIT | -20.59M | -24.65M | -27.63M | -30.21M | -31.66M |
| EBITDA | -20.45M | -24.22M | -26.89M | -29.18M | -30.34M |
| EPS Basic | -16.73 | -19.16 | -21.31 | -23.08 | -24.02 |
| Normalized Basic EPS | -9.80 | -11.79 | -13.14 | -14.27 | -14.77 |
| EPS Diluted | -16.73 | -19.16 | -21.31 | -23.08 | -24.02 |
| Normalized Diluted EPS | -9.80 | -11.79 | -13.14 | -14.27 | -14.77 |
| Average Basic Shares Outstanding | 5.04M | 5.04M | 5.04M | 5.03M | 5.02M |
| Average Diluted Shares Outstanding | 5.04M | 5.04M | 5.04M | 5.03M | 5.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |